NASDAQ:GNLX Genelux (GNLX) Stock Price, News & Analysis → Biden Nomination CANCELED? (From The Freeport Society) (Ad) Free GNLX Stock Alerts $2.71 +0.06 (+2.26%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$2.61▼$2.7250-Day Range$2.62▼$6.4352-Week Range$2.50▼$40.98Volume249,904 shsAverage Volume383,861 shsMarket Capitalization$73.16 millionP/E RatioN/ADividend YieldN/APrice Target$32.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Genelux alerts: Email Address Genelux MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,093.1% Upside$32.33 Price TargetShort InterestBearish12.10% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.12Based on 4 Articles This WeekInsider TradingSelling Shares$477,725 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.91) to ($1.41) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.76 out of 5 starsMedical Sector829th out of 929 stocksPharmaceutical Preparations Industry393rd out of 438 stocks 3.5 Analyst's Opinion Consensus RatingGenelux has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageGenelux has only been the subject of 2 research reports in the past 90 days.Read more about Genelux's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted12.10% of the float of Genelux has been sold short.Short Interest Ratio / Days to CoverGenelux has a short interest ratio ("days to cover") of 12.8, which indicates bearish sentiment.Change versus previous monthShort interest in Genelux has recently increased by 5.17%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGenelux does not currently pay a dividend.Dividend GrowthGenelux does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GNLX. Previous Next 1.6 News and Social Media Coverage News SentimentGenelux has a news sentiment score of -0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Genelux this week, compared to 1 article on an average week.Search Interest5 people have searched for GNLX on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Genelux to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Genelux insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $477,725.00 in company stock.Percentage Held by Insiders11.70% of the stock of Genelux is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 37.33% of the stock of Genelux is held by institutions.Read more about Genelux's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Genelux are expected to decrease in the coming year, from ($0.91) to ($1.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Genelux is -2.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Genelux is -2.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGenelux has a P/B Ratio of 4.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Genelux's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsUnlock Explosive Gains with This Defense StockA massive shift in military technology is happening right now. The Pentagon is investing billions in cutting-edge weaponry, and one under-the-radar company has secured a groundbreaking contract, outmaneuvering the biggest names in defense.Click here to uncover the full story >>> About Genelux Stock (NASDAQ:GNLX)Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.Read More GNLX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GNLX Stock News HeadlinesMay 16, 2024 | insidertrades.comInsider Selling: Genelux Co. (NASDAQ:GNLX) Major Shareholder Sells 3,446 Shares of StockMay 10, 2024 | insidertrades.comInsider Selling: Genelux Co. (NASDAQ:GNLX) Major Shareholder Sells 6,025 Shares of StockMay 2, 2024 | insidertrades.comGenelux Co. (NASDAQ:GNLX) Major Shareholder Sells $20,809.75 in StockMay 2, 2024 | insidertrades.comInsider Selling: Genelux Co. (NASDAQ:GNLX) Major Shareholder Sells 33,061 Shares of StockJune 1 at 7:32 AM | americanbankingnews.comGenelux (NASDAQ:GNLX) Price Target Lowered to $25.00 at BenchmarkMay 24, 2024 | msn.comWhy Genelux Corporation (GNLX) Shares Are Down 40%May 24, 2024 | globenewswire.comGenelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying WarrantsMay 23, 2024 | globenewswire.comGenelux Corporation Announces Proposed Public Offering of Common Stock and WarrantsMay 22, 2024 | americanbankingnews.comGenelux (GNLX) and Its Competitors Financial ContrastMay 16, 2024 | finance.yahoo.comGenelux Corporation (GNLX)May 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Genelux Corp on Strong Trial Progress and Solid FinancialsMay 10, 2024 | investorplace.comGNLX Stock Earnings: Genelux Misses EPS for Q1 2024May 9, 2024 | globenewswire.comGenelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business UpdatesMay 5, 2024 | finance.yahoo.comGenelux Corporation's (NASDAQ:GNLX) market cap rose US$11m last week; individual investors who hold 54% profited and so did insidersApril 20, 2024 | investing.comGenelux Corp insider sells shares worth over $250kApril 17, 2024 | msn.comGenelux (GNLX) Price Target Decreased by 22.96% to 26.52April 2, 2024 | investorplace.comGNLX Stock Earnings: Genelux Misses EPS for Q4 2023April 1, 2024 | globenewswire.comGenelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 19, 2024 | seekingalpha.comAtossa climbs after cancer therapy updateMarch 15, 2024 | msn.comTD Cowen cuts Immuneering to market perform, cites Phase 1 dataMarch 10, 2024 | msn.comCytomX FY 2023 Earnings PreviewFebruary 23, 2024 | benzinga.comGenelux Stock (NASDAQ:GNLX) Insider TradesFebruary 12, 2024 | msn.comG1 Therapeutics stock dives 36% post-market on P3 study updateFebruary 6, 2024 | msn.comGenelux Corp. Unveils Future-Oriented Corporate PresentationFebruary 3, 2024 | msn.comGenelux Corp. Estimates $23.2 Million in Year-End AssetsSee More Headlines Receive GNLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genelux and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/01/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GNLX CUSIPN/A CIK1231457 Webwww.genelux.com Phone805-267-9889FaxN/AEmployees23Year FoundedN/APrice Target and Rating Average Stock Price Target$32.33 High Stock Price Target$40.00 Low Stock Price Target$25.00 Potential Upside/Downside+1,093.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,300,000.00 Net MarginsN/A Pretax Margin-322,287.50% Return on Equity-125.58% Return on Assets-86.03% Debt Debt-to-Equity RatioN/A Current Ratio2.72 Quick Ratio2.72 Sales & Book Value Annual Sales$170,000.00 Price / Sales430.41 Cash FlowN/A Price / Cash FlowN/A Book Value$0.56 per share Price / Book4.84Miscellaneous Outstanding Shares27,000,000Free Float23,838,000Market Cap$73.17 million OptionableNot Optionable Beta-1.18 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Thomas Zindrick J.D. (Age 64)Chairman, CEO & President Comp: $570.99kMs. Lourie S. Zak (Age 60)Chief Financial Officer Comp: $346.19kMs. Caroline Jewett (Age 59)VP & Head of Quality Comp: $269.26kDr. Joseph Cappello Ph.D. (Age 67)Chief Technical Officer Comp: $213.08kMr. Sean Ryder J.D. (Age 54)General Counsel & Corporate Secretary Comp: $380kDr. Yong Yu Ph.D. (Age 52)Senior Vice President of Clinical Development Comp: $242.62kProf. Paul Scigalla M.D. (Age 78)Ph.D., Chief Medical Officer Mr. Ralph Smalling B.Sc. (Age 67)VP & Head of Regulatory Affairs More ExecutivesKey CompetitorsCorMedixNASDAQ:CRMDNature's Sunshine ProductsNASDAQ:NATRMersana TherapeuticsNASDAQ:MRSNADC TherapeuticsNYSE:ADCT23andMeNASDAQ:MEView All CompetitorsInsiders & InstitutionsAladar SzalaySold 17,094 sharesTotal: $62,564.04 ($3.66/share)Aladar SzalaySold 3,446 sharesTotal: $12,474.52 ($3.62/share)Vanguard Group Inc.Bought 24,220 shares on 5/10/2024Ownership: 3.808%SageView Advisory Group LLCBought 18,788 shares on 5/9/2024Ownership: 0.070%Aladar SzalaySold 6,025 sharesTotal: $22,111.75 ($3.67/share)View All Insider TransactionsView All Institutional Transactions GNLX Stock Analysis - Frequently Asked Questions Should I buy or sell Genelux stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genelux in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GNLX shares. View GNLX analyst ratings or view top-rated stocks. What is Genelux's stock price target for 2024? 4 equities research analysts have issued 12 month target prices for Genelux's stock. Their GNLX share price targets range from $25.00 to $40.00. On average, they expect the company's stock price to reach $32.33 in the next year. This suggests a possible upside of 1,093.1% from the stock's current price. View analysts price targets for GNLX or view top-rated stocks among Wall Street analysts. How have GNLX shares performed in 2024? Genelux's stock was trading at $14.01 at the beginning of 2024. Since then, GNLX stock has decreased by 80.7% and is now trading at $2.71. View the best growth stocks for 2024 here. Are investors shorting Genelux? Genelux saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 2,440,000 shares, an increase of 5.2% from the April 30th total of 2,320,000 shares. Based on an average daily trading volume, of 190,100 shares, the days-to-cover ratio is currently 12.8 days. Approximately 12.1% of the shares of the stock are short sold. View Genelux's Short Interest. When is Genelux's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our GNLX earnings forecast. How were Genelux's earnings last quarter? Genelux Co. (NASDAQ:GNLX) issued its earnings results on Thursday, May, 9th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by $0.08. The firm had revenue of $0.01 million for the quarter. When did Genelux IPO? Genelux (GNLX) raised $16 million in an IPO on Thursday, January 26th 2023. The company issued 2,500,000 shares at a price of $6.00-$7.00 per share. The Benchmark Company and Brookline Capital Markets served as the underwriters for the IPO. Who are Genelux's major shareholders? Genelux's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Woodward Diversified Capital LLC (4.04%), Vanguard Group Inc. (3.81%), LifeSteps Financial Inc. (0.16%), Clarity Capital Partners LLC (0.08%) and SageView Advisory Group LLC (0.07%). Insiders that own company stock include Aladar Szalay, Caroline Jewett, Doug Samuelson, John Thomas, John W Smither, Joseph Cappello, Qian Zhang, Sean Ryder, Thomas Zindrick and Yong Yu. View institutional ownership trends. How do I buy shares of Genelux? Shares of GNLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GNLX) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaBiden Nomination CANCELED?The Freeport SocietyNvidia is about to pass AppleWeiss RatingsClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProThe Worst is Yet to Come…Porter & CompanyDems have chosen Biden replacement?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genelux Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
